Health workers collect personal data from a man as they prepare a list during a door-to-door survey for the first shot of COVID-19 vaccine for people above 50 years of age and those with comorbidities near Ahmedabad, December 14, 2020. Photo: Reuters/Amit Dave/File Photo
Mumbai: Many Indians appear hesitant to get vaccinated for COVID-19 as infections have fallen sharply since a mid-September peak and some people are worried about possible side-effects, according to a survey of 18,000 people released on Thursday.
India reported 24,037 new infections on Thursday – fewer than 30,000 for a fourth straight day – taking its total to 9.96 million, the second highest in the world. More than 144,000 people have died.
Until early last month, India had looked set to overtake the infection tally of the United States but the gap between them has since widened significantly. US cases have now risen to more than 16 million.
The government says it could soon approve some of the vaccines that have sought emergency use authorisation, including the Oxford-AstraZeneca one and the Pfizer/BioNTech shot, which is already being used in the United States and Britain.
India wants to roll out vaccines in a few weeks, initially focusing on people more exposed to the virus and over 50, but a survey by citizen survey platform LocalCircles found that about 69% of respondents saw no urgent need to get immunized.
“It appears some of the key reasons for the hesitancy are limited information about side-effects, efficacy levels and a growing belief in parts of the population that COVID cannot affect them because of their high immunity levels,” LocalCircles said in a statement.
Many people in the survey, which had responses from nearly a third of India‘s districts, said they believed “we are moving towards herd immunity”.
Jiaul Haque, a software engineer from the eastern state of Assam, said he thought he had already developed some kind of immunity to COVID-19 and would to see how the various vaccines work on other people before he signs up for one.
“The vaccine has not passed the regular duration of testing,” the 36-year-old said.
“All vaccine companies are in a race against each other, so I’m also concerned about that.”